DUB Inhibitors
Deubiquitinating enzymes (DUBs) are a critical class of proteases that counteract the action of ubiquitin ligases by cleaving ubiquitin chains from target proteins. This process is fundamental to regulating protein stability, localization, and function, thereby influencing a vast array of cellular processes including DNA repair, cell cycle progression, signal transduction, and protein trafficking. The ubiquitin-proteasome system (UPS) is a highly conserved pathway, and DUBs, by controlling the ubiquitination status of proteins, play a pivotal role in maintaining cellular homeostasis. Dysregulation of DUB activity has been implicated in the pathogenesis of numerous diseases, most notably cancer, where DUBs can stabilize oncoproteins or inhibit tumor suppressors. Neurodegenerative disorders, inflammatory conditions, and viral infections also exhibit links to aberrant DUB function. Given their central role in disease, DUBs have emerged as attractive therapeutic targets. Current research into DUB inhibitors is rapidly advancing, with a significant portion of efforts focused on identifying potent and selective inhibitors for specific DUBs.
Several DUBs, such as USP7, USP14, USP10, and OTUB1, have been prioritized due to their well-established roles in cancer. Preclinical studies have demonstrated the anti-cancer efficacy of DUB inhibitors in various tumor models, often leading to cell cycle arrest, apoptosis, and reduced tumor growth. Some DUB inhibitors have progressed into early-phase clinical trials, primarily for hematological malignancies and solid tumors, though none have yet received regulatory approval. The development pipeline includes compounds targeting different DUB families, reflecting the complexity of the DUB landscape. Classifications of DUB inhibitors often depend on their mechanism of action and selectivity. Broadly, they can be categorized into reversible and irreversible inhibitors. Reversible inhibitors bind non-covalently to the DUB active site, while irreversible inhibitors form a covalent bond, leading to permanent inactivation.
Selectivity is a major challenge, as many DUBs share structural similarities, particularly within their catalytic domains. Inhibitors are therefore often classified by the specific DUB they target (e.g., USP7 inhibitors, USP14 inhibitors) or by their selectivity profile across different DUBs. Small molecule inhibitors represent the predominant class, but peptide-based inhibitors and PROTACs (proteolysis-targeting chimeras) that induce proteasomal degradation of DUBs are also under investigation. Key research tool compounds, such as P5091 (a USP7 inhibitor) and b-AP15 (a dual USP14/Ubp6 inhibitor), have been instrumental in validating DUBs as therapeutic targets. However, significant challenges remain. Off-target inhibition due to lack of selectivity can lead to dose-limiting toxicities, affecting essential cellular processes regulated by other DUBs. Furthermore, cancer cells can develop resistance mechanisms to DUB inhibitors, necessitating combination therapy strategies.
Combining DUB inhibitors with chemotherapy, targeted therapies, or immunotherapies is a promising avenue to enhance efficacy and overcome resistance. Understanding the precise roles of individual DUBs in specific disease contexts and developing highly selective inhibitors are crucial for realizing the full therapeutic potential of this target class.
